Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

B.M. Tijink, T. Laeremans, M. Budde, W.M. Stigter-van, T. Dreier, H.J. de Haard, C.R. Leemans, G.A.M.S. van Dongen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2288-2297
JournalMolecular Cancer Therapeutics
Volume7
Issue number8
DOIs
Publication statusPublished - 2008

Cite this

@article{c600da2cf702463fac483de93ba160c1,
title = "Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology",
author = "B.M. Tijink and T. Laeremans and M. Budde and W.M. Stigter-van and T. Dreier and {de Haard}, H.J. and C.R. Leemans and {van Dongen}, G.A.M.S.",
year = "2008",
doi = "10.1158/1535-7163.MCT-07-2384",
language = "Undefined/Unknown",
volume = "7",
pages = "2288--2297",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. / Tijink, B.M.; Laeremans, T.; Budde, M.; Stigter-van, W.M.; Dreier, T.; de Haard, H.J.; Leemans, C.R.; van Dongen, G.A.M.S.

In: Molecular Cancer Therapeutics, Vol. 7, No. 8, 2008, p. 2288-2297.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

AU - Tijink, B.M.

AU - Laeremans, T.

AU - Budde, M.

AU - Stigter-van, W.M.

AU - Dreier, T.

AU - de Haard, H.J.

AU - Leemans, C.R.

AU - van Dongen, G.A.M.S.

PY - 2008

Y1 - 2008

U2 - 10.1158/1535-7163.MCT-07-2384

DO - 10.1158/1535-7163.MCT-07-2384

M3 - Article

VL - 7

SP - 2288

EP - 2297

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 8

ER -